Intravenous human immunoglobulin (pH4) (Sinopharm)
静注人免疫球蛋白 (pH4)（国药集团）
Report date: 2023/02/26 21:49:54
Base Information
Drug NameIntravenous human immunoglobulin (pH4) (Sinopharm)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesSinopharm Shanghai Plasma-Derived Biotherapies Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesSinopharm Shanghai Plasma-Derived Biotherapies Co Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A